Influence of valsartan on clinical and instrumental parameters in patients suffering from chronic heart failure with mid-range ejection fraction

Purpose: to establish the effectiveness of valsartan in patients with chronic heart failure with mid-range ejection fraction from the standpoint of influencing the clinic, the parameters of central hemodynamics and the level of natriuretic peptide. Material and Methods. Our study included 45 patients with CHF with mid-range ejection fraction, with NYHA (New York Heart Association) functional class II (FC). All patients underwent a comprehensive clinical and standard echocardiographic examination. Valsartan was administered in titrated dosages up to the maximum tolerated ortarget daily dose in accordance with the recommendations. The observation period was one year. Results. During the observation period, 89% of patients switched from FC II to FC I of CHF (p<0.001), the left ventricular (LV) ejection fraction increased from 46 (44-47) % to 55 (53-60) % (p<0,05), the level of natriuretic peptide decreased from 455 (397-513) pg/ml to 210 (146-343) pg/ml (p<0.05). Conclusion. The use of valsartan in patients with CHF with mid-range ejection fraction improves the clinical condition and parameters of central hemodynamic during a year of observation.